Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPLENDOR: Effects of Pioglitazone on Endothelial Progenitor Cells in Type 2 Diabetes with Vascular Complications
2007-003077-44Phase 4Completed
- Sponsor
- Takeda
- Start
- Jul 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of pioglitazone in type 2 diabetes mellitus (T2DM) and cardiac morbidity (2 arms), sponsored by Takeda. Primary endpoint: Change in circulating endothelial progenitor cell number. Started Jul 2008; status: completed.
02
Drugs
pioglitazone
03
Conditions
type 2 diabetes mellitus (T2DM)cardiac morbidity
Beyond the preview
Go deeper on 2007-003077-44.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003077-44.